Die Abschätzung der Prognose für Patienten, insbesondere Kinder mit onkologischen Erkrankungen stellt eine große Herausforderung an die behandelnden Ärzte dar. Vor Beginn einer Therapie werden daher viele Informationen gesammelt, um einen Patienten möglichst gut in eine vordefinierte Risikogruppe stratifizieren und dementsprechend eine mehr oder weniger intensive Therapie anbieten zu können. Diese Einteilungen sind allerdings für keinen Malignomtyp mit 100%-iger Sicherheit möglich. Das ist die Ursache dafür, dass auch in niedrige Risikogruppen eingeteilte Patienten nicht auf die Therapie ansprechen und einen unvorhergesehen schlechten Verlauf zeigen können. Auf der anderen Seite scheint es Patienten zu geben, die trotz initial schlecht eingeschätzter Prognose einen überaschend guten Verlauf nehmen, auf die Therapie gut ansprechen und letztlich geheilt werden können. Einen Beitrag zu leisten, um die Stratifizierung für Kinder, die an einem Neuroblastom erkrankt sind, zu verbessern und damit zu vermeiden, dass einige Patienten unter- oder andere Patienten übertherapiert werden müssen, ist das Ziel dieser Habilitationsarbeit. Zu diesem Zweck wurden differentielle, molekulare Marker in primären humanen Neuroblastomen identifiziert und deren prognostische Bedeutung dargestellt. Einzelne dieser Marker (differentiell expremierte mRNAs) wurden in Zellkultursystemen funktionell untersucht, um deren zellbiologische Funktion, die der jeweiligen prognostischen Bedeutung zugrunde liegen kann zu erklären. Desweiteren konnten genomische Merkmale des amplifizierten genomischen Abschnittes auf Chromosom 2p25 um MYCN beschrieben werden. Darauf basierend konnte eine patientenindividuelle und tumorzellspezifische PCR entwickelt werden (AFS-PCR), die sich als Marker für den Nachweis einer minimalen Resterkrankung eignet.

To understand the functional interactions between the TrkA and p75 nerve growth factor (NGF) receptors, we employed several lines of investigation including biophysical, biochemical and cellular assays. A high-affinity nerve growth factor (NGF) receptor is thought to be a complex of two receptors, p75 and the receptor tyrosine kinase, TrkA. The existence of a gp75-TrkA complex was demonstrated by a copatching technique. p75 on the surface of intact cells is patched with an anti-p75 antibody and fluorescent secondary antibody, the cells are then fixed to prevent further antibody-induced redistributions, and the distribution of TrkA is probed with an anti-TrkA antibody and fluorescent secondary antibody. We utilize a baculovirus-insect cell expression system, which allows high level expression of wild-type and mutated NGF receptors. TrkA and p75 copatch in both the absence and presence of NGF. This association is specific, since p75 does not copatch with other tyrosine kinase receptors, including TrkB, platelet-derived growth factor receptor-β and Torso (Tor). To determine which domains of TrkA are required for copatching, we used a series of TrkA-Tor chimeric receptors and show that the extracellular domain of TrkA is sufficient for copatching with p75. A chimeric receptor with TrkA transmembrane and intracellular domains shows partial copatching with p75. Deletion of the intracellular domain of p75 decreases but does not eliminate copatching. A point mutation that inactivates the TrkA kinase has no effect on copatching, indicating that this enzymatic activity is not required for association with p75. Hence, although interactions between the p75 and TrkA extracellular domains are sufficient for complex formation, interactions involving other receptor domains also play a role. To study what signal transduction mechanisms were activated by the two receptors to bring about differentiation and survival, we stably transfected LAN5 neuroblastoma cells with an expression vector for ET-R, a chimeric receptor with the extracellular domain of the epidermal growth factor receptor (EGFR) and the TrkA transmembrane and intracellular domains. EGF activated the ET-R kinase and induced partial differentiation. NGF, which can bind to endogenous p75, did not induce differentiation, but enhanced the EGF-induced response, leading to differentiation of almost all of the cells. A mutated NGF, 3T-NGF, that binds to TrkA but not to p75 did not synergize with EGF. Enhancement of EGF-induced differentiation required at least nanomolar concentrations of NGF, consistent with the low-affinity p75 binding site. EGF may induce a limited number of neuronal cells because it also enhances apoptosis. Both NGF and a caspase inhibitor reduced apoptosis and, thereby, enhanced differentiation. NGF appears to enhance survival through the phosphatidylinositol-3 kinase (PI3K) pathway. Consistent with this hypothesis, Akt, a downstream effector of the PI3K pathway, was hyperphosphorylated in the presence of EGF+NGF. These results demonstrate that TrkA kinase initiates differentiation, and p75 enhances differentiation by rescuing differentiating cells from apoptosis via the PI3K pathway. Even though both EGF and NGF are required for differentiation of LAN5/ET-R cells, only NGF is required for survival of the differentiated cells. In the absence of NGF, the cells die by an apoptotic mechanism, involving caspase-3. An anti-p75 antibody blocked the survival effect of NGF. Brain-derived neurotrophic factor also enhanced cell survival, indicating that in differentiated cells, NGF acts through the p75 receptor to prevent apoptosis.

Le neuroblastome est cancer du jeune enfant se développant au sein du système nerveux périphérique sympathique. Cette tumeur est caractérisée par sa grande hétérogénéité clinique : allant de formes régressant spontanément aux tumeurs de haut-risque, réfractaires aux traitements les plus agressifs. La survie à long terme des patients présentant un neuroblastome de haut-risque reste par ailleurs inférieure à 50%, ce qui souligne la nécessité de trouver de nouveaux traitements afin d’améliorer leur prise en charge thérapeutique.Récemment, en définissant le paysage épigénétique des cellules de neuroblastome, nous avons observé la présence de super-enhancers (SE). La caractérisation du paysage des SE dans les lignées de neuroblastome nous a permis de révéler l’hétérogénéité cellulaire du neuroblastome, composée de deux identités distinctes : noradrénergique et mésenchymateuse. Chacune des identités cellulaires est caractérisée par un circuit de régulation transcriptionnelle (CRC) : les facteurs PHOX2B, HAND2 et GATA3 définissent l’identité noradrénergique alors que les facteurs de la famille AP-1 gouvernent l’identité mésenchymateuse. Nous avons par ailleurs montré la différence de sensibilité aux chimiothérapies classiquement utilisées en clinique entre ces deux types cellulaires, avec une résistance accrue des cellules mésenchymateuses.Mon travail de thèse porte sur la caractérisation du rôle des facteurs de transcription PHOX2B et GATA3 dans l’établissement et le maintien de l’identité noradrénergique des cellules de neuroblastome. J’ai réalisé leur knock-out par CRISPR-Cas9 dans la lignée noradrénergique SH-SY5Y. L’inactivation de PHOX2B ne modifie ni le programme transcriptionnel ni le phénotype des cellules, arborant une identité noradrénergique. En revanche, les cellules inactivées pour GATA3 possèdent un phénotype cellulaire mésenchymateux ainsi que des capacités de migration, d’invasion et de résistance aux chimiothérapies. Le knock-out de PHOX2B et GATA3 entraine une diminution de la prolifération cellulaire, traduisant le phénomène d’addiction transcriptionnelle des cellules cancéreuses. La caractérisation du paysage épigénétique des cellules inactivées pour GATA3 démontre leur reprogrammation de l’identité noradrénergique vers l’identité mésenchymateuse avec l’effondrement des SE noradrénergiques ainsi que l’acquisition de SE mésenchymateux. GATA3 est donc indispensable pour le maintien de l’identité noradrénergique in vitro.Les résultats générés lors de ma thèse montrent que les facteurs de transcription impliqués dans un même CRC possèdent des rôles distincts dans l’identité cellulaire. La caractérisation de la dynamique de reprogrammation ainsi que des facteurs impliqués dans ce processus nous permettrons de mieux comprendre les phénomènes de plasticité cellulaire à l’origine de la progression tumorale et de la rechute thérapeutique des patients. / Neuroblastoma is a pediatric tumor of the peripheral sympathetic nervous system characterized by its diversity of clinical presentations from spontaneous regression to highly aggressive tumors. Currently, the overall survival of high-risk neuroblastoma patients remains under 50% which highlight the need to find new therapeutic approaches to improve patient outcome.Recently, we defined the epigenetic landscape of neuroblastoma cell lines and observed the presence of super-enhancers (SE). The characterization of the SE landscape let us to define the heterogeneity of neuroblastoma cell identity with the presence of noradrenergic and mesenchymal cells. Both cell identities are governed by a core regulatory circuitry (CRC), composed by PHOX2B-HAND2-GATA3 in the noradrenergic cells and by AP-1 transcription factors in the mesenchymal cells. We also demonstrate the different behaviors of the cells regarding chemotherapy treatments with a higher resistance of the mesenchymal cells.My thesis aimed at deciphering the role of PHOX2B and GATA3 transcription factors in the establishment and the maintenance of the noradrenergic identity of neuroblastoma cells. To do this, PHOX2B and GATA3 were knock-out by CRISPR-Cas9 in the noradrenergic SH-SY5Y cell line. PHOX2B knock-out has no major impact neither on the transcriptomic profile nor the phenotype of the cells. PHOX2B knock-out cells still maintain their noradrenergic identity. In contrast, GATA3 knock-out cells harbor a mesenchymal phenotype showing higher ability to migrate, invade and being pore resistant to chemotherapy than control SH-SY5Y cells. Both PHOX2B and GATA3 knock-out decrease the SH-SY5Y cell proliferation in vitro and in vivo, which highlight the transcriptional dependency of the noradrenergic cells for their identity-related transcription factors. The characterization of the epigenetic landscape of GATA3 knock-out cells revealed their reprograming from the noradrenergic to the mesenchymal identity with the loss of noradrenergic SE and the acquisition of mesenchymal SE. These results demonstrate that GATA3 is essential for the maintenance of the noradrenergic identity in vitro.Altogether, these results show that transcription factors involved in a CRC can have distinct role in the cell identity. The characterization of the reprogramming dynamics as well as the factors involved in this process will allow us to better understand the cellular plasticity involved in the tumor progression and patient relapse.

The aim of the current study is to study characteristics of high-risk cancer cells within the childhood disease neuroblastoma (NB) by mapping regrowth after treatment with the chemotherapy doxorubicin (doxo). The cell-line SK-N-BE(2)-C (BE(2)-C) was used as a model. Results from a previous study by Hultman et al., (2018) have indicated that while a majority of BE(2)-C cells could be shown resilient to a 1 μM dose of doxorubicin (doxo), only a very small fractions had the capacity for immediate replication following a single or double treatment of doxo (“remaining replicating cells”; RRC). The current study aims to investigate if RRC are responsible for regrowth. Cultured BE(2)-C cells were exposed to doxo and labelled with the nucleoside analogues EdU (5-ethynyl-2’-deoxyuridine) and BrdU (5-bromo-2-deoxyuridine). The results from the current study indicated that the RRC subpopulation might not be responsible for regrowth since the nucleoside labelling was not shown to be present in the cells of the regrowing colonies. However, technical challenges, e.g. the settings of thresholds for EdU and BrdU detection, in combination with the dilution of DNA markers in replication, call for further studies using additional methods, e.g. isotope markers, in order to firmly conclude that other subpopulation(s) than the RRC population are responsible for regrowth. Apart from studying cell populations responsible for regrowth, a pilot study was performed including another combination of treatment using an ATM-inhibitor (KU-60019) together with the chemotherapy doxo. There were some measurement points missing, but the current results indicate that regrowth is postponed when the ATM-inhibitor is added in combination with single or double treatment of doxo. The research procedures and processes involved in this thesis, are similar to those included in the syllabi for the natural science subjects for the upper secondary school. This underlines the importance of studying inquiry and laboratory work. A literature review was performed, analysing current research on open-and closed ended laboratory work. Ten research articles were collected and characterized by natural science subject, type of laboratory style (open or closed) and student learning competences. Findings from the current study indicate that open-ended laboratory work promotes student interest in the subject. The learning competences problem-solving ability and procedure ability are most commonly studied in laboratory work based on the results from the current study. / Syftet med studien är att studera hög-risk cancerceller inom barncancersjukdomen neuroblastom (NB), genom att kartlägga återväxt efter kemoterapi-behandling med doxorubicin (doxo). En multiresistent neuroblastom cell-linje med hög-risk egenskaper, SK-N-BE(2)-C( BE[2]-C), användes som modell. Enligt en tidigare studie på BE(2)-C celler, utförd av Hultman et al., (2018), kan efter en enkel eller dubbelbehandling med doxo majoriteten av cellerna överleva, men endast en mycket liten andel kan också omedelbart fortsätta dela sig. Dessa celler benämndes som ”kvarvarande replikerande celler” (RRC). I denna studie undersöktes hypotesen att RRC är ansvariga för återväxt efter doxo-terapi, hypotetiskt återspeglande situationen vid återfall hos patienten. BE(2)-C celler odlades in vitro i petriskålar, behandlades med doxo, och analyserades sedan i mikroskop genom att använda två kemiska markörer för cell-delning; EdU (5-etynyl-2’-deoxyuridin) och BrdU (5-bromo-2-deoxyuridin). Intressant nog, men något oväntat, indikerar resultaten att RRC troligen inte är ansvariga för återväxt. Detta skulle då tyda på att återväxten orsakas av andra cellpopulationer, utan förmåga att omedelbart efter kemoterapin fortsätta dela sig. Dock förekom tekniska utmaningar med valda metoder, t.ex. gränsvärdena för EdU- och BrdU-detektering, i kombination med utspädningen av DNA-markörer vid replikation. Därför krävs ytterligare studier med användning av andra metoder, t.ex. isotopmarkörer, för att fastställa vilka subpopulationer som är ansvariga för återväxt. Utöver att studera cellpopulationer ansvariga för återväxt så genomfördes även en pilotstudie med en kombination av doxo och annan typ av kemoterapi riktad mot cellens förmåga att reparera DNA skador; en ATM-inhibitor (KU-60019). Pilotstudien indikerar att återväxten av BE(2)-C förskjuts vid närvaro av KU-60019, både i kombination med enkel eller dubbelbehandling av kemoterapin doxo. Det naturvetenskapliga arbetssättet i denna studie, vilket inkluderas i ämnesplanerna för de naturvetenskapliga ämnena för gymnasieskolan, understryker betydelsen av att studera laborativt arbete. En litteraturstudie genomfördes med fokus på öppna och slutna laborationer. Tio forskningsartiklar analyserades och karaktäriserades; typ av laborationsstil (öppen eller sluten) och elevers lärandekompetenser. Resultatet från denna studie indikerar att öppna laborationer bidrar till att öka elevers intresse. Vidare visar resultatet att laborativt arbete i skolan inkluderar utvecklingen av främst problemlösningsförmågan och procedurförmågan. Forskningsprocedurer och processer involverade i detta examensarbete diskuteras.

Neuroblastom är en barncancer som uppstår ur det sympatiska nervsystemet och drabbar omkring 15 barn i Sverige varje år. Högriskvarianten är associerad med mycket hög dödlighet och risk för återfall, vilket tros ha att göra med att tumörernas ovanligt heterogena sammansättning tillåter resistenta subpopulationer att motstå konventionella behandlingsmetoder. Tidigare forskning har identifierat rubbade mekanismer för celldelning som ett tillvägagångssätt för tumörcellerna att överleva DNA-skador som kemoterapeutiska droger orsakar. I detta masterprojekt analyserades fem ultra-högrisk neuroblastomcellinjer i syfte att belysa deras progression genom celldelningen efter behandling med doxorubicin och/eller gemcitabin. Vidare identifierades ataxia telangesia mutated (ATM) serine/threonine kinase som ett essentiellt protein vid inhibering av celldelningen och i samband med reparation av DNA-skador, vilket bekräftades av förhöjt uttryck av fosforylerat ATM i alla fem cellinjer efter behandling med doxorubicin, gemcitabin, och/eller en kombination av båda. Återväxt av tumörcellerna efter inhibering av fosforylerat ATM i kombination med doxorubicin och gemcitabin analyserades sedan, och fördröjd återväxt noterades i en av cellinjerna efter kombinationsbehandling. Sammantaget har nya mekanismer för behandlingsresistens hos tumörceller identifierats och alternativa kombinationsbehandlingar har visat effekt på en av fem testade neuroblastomcellinjer. / Neuroblastoma is a pediatric cancer of the sympathetic nervous system that afflicts around 15 children annually in Sweden. Despite aggressive treatment, high-risk neuroblastoma is associated with a mortality of 50% and relapse rate of up to 60%, emphasizing the need for novel treatment options. In this study, fluoresce activated cell sorting was used to analyze cell cycle progression in five ultra-high-risk neuroblastoma cell lines: BE(2)-C, Kelly, SK-N-AS, SK-N-DZ, and SK-N-FI, post-treatment with doxorubicin and gemcitabine. In line with previous research, doxorubicin primarily induced cell cycle arrest in G2/M-phase and gemcitabine in the S-phase. Combined, the compounds induced varied effects, with accumulation primarily in the G1-and S-phase. Immunoblotting revealed elevated levels of phosphorylated ATM (pATM), a key regulator of cell cycle arrest and DNA damage signaling, across all five cell lines post-treatment to doxorubicin, gemcitabine, and/or the combination, indicating its vital role in their survival. Kelly stood out in both cell cycle progression and ATM phosphorylation, exhibiting minimal to no changes in cell cycle accumulation or pATM expression when exposed to the combined treatment, despite reacting to both monotherapies. These results may indicate that Kelly might implement an alternative mechanism of regulation compared to the remaining cell lines. To explore targeted inhibition of pATM, we employed the ATM kinase inhibitor KU-55933, which in BE(2)-C cells reduced expression levels of pATM when combined with doxorubicin, but not gemcitabine or the combination. Regrowth assays showed increased efficacy of doxorubicin and gemcitabine upon addition of the ATM kinase inhibitor KU-55933 in one of the tested cell lines in comparison to doxorubicin alone. However, longer incubation time is needed before the effect can be fully evaluated. These findings shed light on the differential cell cycle behavior in high-risk neuroblastoma cell lines exposed to combination therapy and suggest a vital role of ATM in the DNA damage response following doxorubicin and gemcitabine treatment. Further investigations are warranted to explore alternative strategies for enhancing the effectiveness of doxorubicin and gemcitabine in the treatment of this aggressive cancer subtype.

Polysialic acid is aunique carbohydrate that decorates the surface of the neural cell adhesion molecule. Polysialic acidis an onco-developmental antigen, expressed in tumours principally of neuroendocrine origin, notably neuroblastoma,strongly correlating with invasion and metastasis. Polysialylation is regulated by two polysialyltransferase enzymes, PST(ST8SiaIV)and STX(ST8SiaII),withSTX dominant in cancer. Post-development polysialic acid expression is only found at low levels in the brain, thus this could be a novel target for cancer therapy. It is hypothesized that inhibition of polysialyltransferasecould lead to control of tumour dissemination and metastasis.The aims of this thesis were to develop tools and in vitro assays to screen novel polysialyltransferaseinhibitors. A panel of tumour cell lines were characterised in terms of growth parameters (using the MTT assay) and polysialic acid expression. This includes a pair of isogenic C6 rat glioma cells (C6-STX and C6-WT) and naturally polysialic acid expressing neuroblastoma cells(SH-SY5Y). Following this, an in vitro assay was validated to screen modulation of polysialic acid expression by removing pre-existing polysialic acid expression using endoneuraminidase N and evaluated the amount of re-expression of polysialic acid using immunocytochemistry. Then, a functional assay was developed and validated for invasion, the matrigel invasion assay. Cytidine monophosphate (tool compound) significantly reduced polysialic acidsurface expression and invasion. A panel of six novel polysialyltransferase inhibitors was screened for cytotoxicity, polysialic acidsurface expression and invasion. Of the potential polysialyltransferase inhibitorsevaluated, ICT3176 and ICT3172 were identified from virtual screening of Maybridge library and were emerged as the most promising inhibitors, demonstrating significant (p<0.05)reduction in cell-surface polysialic acidre-expression and invasion in polysialic acid expressing cells.Furthermore, the specificity of compounds for polysialyltransferase (α-2,8-sialyltransferase) over othermembers of the wider sialyltransferase family (α-2,3-and α-2,6-sialyltransferases) was confirmed using differential lectin staining. These results demonstrated that small molecule inhibitors as STX is possible and provides suitable in vitrocell based assays to discovery more potent derivatives.

Neuroblastoma (NB), an extracranical solid tumor, is among the most prevalent cancers affecting children, particularly those under the age of five. High-risk NB presents a survival rate just below 50 %. Angiogenesis, a crucial process in NB, is induced by various pro-angiogenic factors. The compound SU11657 has demonstrated efficacy in inhibiting angiogenesis and tumor progression. Tumor-associated macrophages (TAMs) and Tumor-associated neutrophils (TANs) contribute to tumor progression, including angiogenesis, and their heightened levels within the tumor has been correlated with a poor clinical prognosis. This study aimed to quantify TANs and TAMs in NB tumors through manual assessment and the development of an automated digital image analysis. Unfortunately, due to time constraints, TAMs were not subjected to detailed analysis. Immunohistochemistry using antibody ab2557 and DAB staining was employed, and cell content analysis was performed through both manual assessment and digital analysis using QuPath. Successful differentiation of TANs was achieved with ab2557. The manual assessment observed a decrease of TANs between the control and treatment groups in UB7 and UB8, with UB7 being statistically significant (p&lt;0.05), based on a two-tailed t-test. QuPath analysis noted increases in the percentages of TANs between the control and treatment groups, with the t-tests being non-significant (p&gt;0.05). While digital image analysis is gaining importance in clinical applications, imperfections persist, underscoring the imperative for further research and development to accurately distinguish biomarkers.

No description available.

The combinatorial code of cPcdh isoforms creates a diversified cell-surface molecular signature for cell-cell recognition in neural networks. This genetic architecture, combined with a regulated expression pattern and trans-homophilic binding properties, provides insights into cell specialization and signaling. Anomalies in cPcdhs, which include genetic mutations, epigenetic modifications, structural variations, and altered gene expression profiles, are associated with several neurological, neuropsychiatric, and systemic conditions, highlighting the importance of cPcdh investigations. This study focuses on the transcriptional regulation of the Pcdhα gene cluster. Each neuron displays a specific Pcdhα alternate exon repertoire, necessitating an understanding of the transcriptional dynamics. Using the SK-N-SH human neuroblastoma cell line and methodologies such as cRNA-seq and Start-Seq, these dynamics are examined. The application of CRISPR-Cas9 gene editing and a dCas9-VPR gain-of-function assay in the HEK293T cell line reveals the role of as-lncRNA and its interaction with DNA methylation within the Pcdhα gene cluster. This study identifies the role of noncoding as-lncRNA in RNA transcription and provides information on CTCF binding and Pcdhα promoter activation. The research also examines the gastrointestinal domain, as cPcdhs are linked to various diseases. Shifting focus from the canonical realm of the CNS, the research embarks on a preliminary yet pivotal exploration of the gastrointestinal domain. As cPcdhs intersect with a plethora of diseases, an incisive understanding of their expression could yield revelations into tissue susceptibilities with potential disease ramifications. Employing a novel single-domain antibody technique coupled with immunohistochemistry, the endeavor casts a precise lens into the gastrointestinal expression dynamics of Pcdhα and Pcdhγ. These insights not only fortify the understanding of cPcdh within neural structures but also beckon a deeper inquiry into their multifaceted biological roles.

Neuronal alterations resulting from exposure to Parkinsonian-inducing 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an in vitro model SH-SYSY human neuroblastoma cells were explored using cytotoxic effects, neurochemical changes and pathological injury as endpoints. The results suggested that: MPTP entered the SH-SYS5Y human neuroblastoma cells through a non-dopamine transport mechanism, and was metabolized to 1-methyl-4-phenyl-2,3-dihydropyridium (MPDP⁺) and 1-methyl-4-phenylpyridium (MPP⁺) by monoamine oxidase (MAO). MPP⁺, the neurotoxic analog of MPTP, was taken up into cells through a dopamine (DA) uptake mechanism. MPTP, via its metabolite MPP⁺, inhibited NADH dehydrogenase activity. The MPTP-induced alterations of morphology included formation of blebs, attenuated neutrites, abnormal mitochondria with electron-density of matrix and disorganization of cristae, and abnormal aggregation of filamentous material of the cytoskeleton. MPTP was neurotoxic to the dopaminergic system, inhibiting monoamine oxidase (MAO) activity, and decreasing levels of dopamine (DA) and other catecholamines. In addition, MPTP enhanced ³H-DA release from cells, and its metabolite MPP⁺ inhibited ³H-DA uptake. MPTP was found to directly act on the cholinergic system in SH-SY5Y cells, causing dose-related decreases in the binding at muscarinic and nicotinic receptors. MPTP also inhibited acetylcholinesterase (AChE) activity and increased choline levels. The MPTP-induced increase in DA release and the decreases in catecholamines in SH-SYSY cells were blocked by pretreatment with acetylcholine receptor antagonists atropine and d-tubocurarine. MPTP caused increases in tau proteins, and also caused an increased expression of the reverse transcriptase polymerase chain reaction (RT-PCR) product after treatment for 2 to 5 days at 10⁻³ to 10⁻⁴ M. The results, for the first time, demonstrated that MPTP affected cytoskeletal associated tau protein and altered its mRNA. These results demonstrated that the human neuroblastoma cell line, SH-SYSY, can be used as an in vitro model for the study of the neurotoxicity of MPTP, including the mechanisms associated with exposure to this neurotoxicitant. / Ph. D.